Fine Eugene J, Feinman Richard David
a 1 Department of Nuclear Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.
b 2 SUNY Health Sciences Center, Brooklyn, NY 11203, USA.
Expert Rev Endocrinol Metab. 2015 Jan;10(1):15-24. doi: 10.1586/17446651.2014.960392. Epub 2014 Sep 22.
We propose that dietary carbohydrate restriction, particularly ketogenic diets, may provide benefit as a therapeutic or preventive strategy in cancer, alone or as an adjunct to pharmacology. The argument derives from several points of evidence: There is a close association between cancer and both diabetes and obesity. Extensive evidence shows that low carbohydrate diets are the most effective dietary treatment of Type 2 diabetes and dietary adjunct in Type 1. Such diets also target all the markers of metabolic syndrome. Finally, de facto reduction in carbohydrate likely contributes to total dietary restriction, which is effective in the prevention and treatment of cancer. The idea is consistent with recent interest in treating cancer with drugs that target diabetes. To move forward, we must understand obesity and diabetes as response to a hyperglycemic state rather than simply a cause of downstream effects.
我们提出，限制膳食碳水化合物，特别是生酮饮食，无论是单独使用还是作为药理学的辅助手段，都可能作为一种治疗或预防癌症的策略而带来益处。这一观点源于多个证据要点：癌症与糖尿病和肥胖症之间存在密切关联。大量证据表明，低碳水化合物饮食是治疗2型糖尿病最有效的饮食疗法，也是1型糖尿病的饮食辅助疗法。此类饮食还针对代谢综合征的所有指标。最后，事实上减少碳水化合物摄入可能有助于总体饮食限制，而这对癌症的预防和治疗是有效的。这一观点与近期使用针对糖尿病的药物治疗癌症的研究兴趣相一致。为了取得进展，我们必须将肥胖症和糖尿病理解为对高血糖状态的反应，而不仅仅是下游效应的原因。
